Table 2.
Changes in the clinical and laboratory parameters of heart failure over five years of ARNi administration.
| Parameters | Baseline | Fifth year | P value |
|---|---|---|---|
| ARNi dosage (twice a daily) (%) | |||
| Cessation | N/A | 12 (16%) | P < .001 |
| 50 mg | 51 (68%) | 11 (14,7%) | |
| 100 mg | 24 (32%) | 21 (28%) | |
| 200 mg | 0 (0,0%) | 31 (41,3%) | |
| Potassium (mmol/L) | 4.34 ± 0.43 | 4.38 ± 0.45 | P = 0.6 |
| Creatinine (mg/dL) | 1.08 ± 0.31 | 1.14 ± 0.35 | P = .057 |
| eGFR (mL/min per 1.73 m2) | 72.46 ± 22.72 | 67.91 ± 21.83 | P = .019 |
| PNI | 36.42 ± 15.78 | 38.28 ± 15.85 | P = .077 |
| NT-proBNP (pg/mL) | 3404 (1750–11,956) | 858 (270–2072) | P < .001 |
| Ejection fraction (%) | 29.12 ± 6.79 | 38.04 ± 7.21 | P < .001 |
| Number of annual hospitalizations | 2.26 ± 0.21 | 0.58 ± 0.11 | P < .001 |
| Functional class (NYHA) (%) | |||
| I | 1 (1.3%) | 21 (28%) | P < .001 |
| II | 29 (38.7%) | 42 (56%) | |
| III | 34 (45.3%) | 7 (9.3%) | |
| IV | 11 (14.7%) | 5 (6.7%) | |
| Dose of furosemide use (mg) | 40 (0–40) | 20 (0–40) | P < .001 |
ARNi = angiotensin receptor neprilysin inhibitor, eGFR = estimated glomerular filtration rate, NT-proBNP = N-terminal pro-brain natriuretic peptide, NYHA = New York Heart Association, PNI = prognostic nutritional index.